Navigation Links
SuperFect Transfection Reagent

The proven activated dendrimer for transfection of a broad range of cell lines

Features and benefits
  • Fast procedure and easy handling
  • Suitable for a broad range of cell lines
  • Transfection in the presence of serum (see figure "Serum and DNA Quantity vs. Transfection Efficiency")
  • High transient and stable transfection efficiencies
  • Excellent reproducibility due to precise size and defined shape of activated dendrimers

Serum and DNA Quantity vs. Transfection Efficiency



Influence of serum and DNA quantity on transfection using SuperFect Reagent. 2 x 104 COS-7 cells were seeded per well in 96-well plates one day prior transfection. Cells were transfected using 0.12.0 g of a beta-galactosidasereporter plasmid and 3 l SuperFect Reagent per well, in either the presence or absence of serum. Each bar represents the average efficiency from four replicates assayed 48 h post-transfection.

Principle

SuperFect Reagent consists of activated-dendrimer molecules with a defined spherical architecture (1). Branches radiate from a central core and terminate at charged amino groups which can then interact with negatively charged phosphate groups of nucleic acids (see figure "Activated-Dendrimer Structure"). SuperFect Reagent assembles DNA into compact structures (see figure "SuperFectDNA Interaction") that bind to the cell surface and are taken into the cell by nonspecific endocytosis. The reagent buffers the pH of the end osome, leading to pH inhibition of endosomal nucleases, which ensures stability of SuperFectDNA complexes.

Due to highly controlled chemical synthesis the activated-dendrimer molecules in SuperFect Reagent have a precise size and a defined shape. This ensures consistent transfection-complex formation and reproducible transfection results.

Activated-Dendrimer Structure

Schematic representation of an activated dendrimer (1). Note the highly branched structure.
SuperFectDNA Interaction
Model of the SuperFectDNA complex. SuperFect Reagent (purple balls) interacts with DNA (black) to form a ring-like (toroid-like) structure. The upper right section of the illustration shows naked DNA, the lower section shows the interaction between dendrimers and DNA inside the complex, and the upper left section shows the final complete coverage of DNA within the complex. Procedure

SuperFect Transfection Reagent is provided as a ready-to-use solution. The reagent is simply added to the DNA solution, mixed, and incubated for 510 minutes to allow SuperFectDNA complexes to form. The complexes are mixed with growth medium (which can contain serum and antibiotics), and added directly to the cells. After a 23 hour incubation, a medium change is performed and the cells are incubated for expression of the transfected gene.

Applications

SuperFect Re agent is suitable for transient and stable transfection of a broad range of cell lines (see figure "Transfection of Neuronal PC-12 Cells Using SuperFect Reagent"). A searchable list of cell lines successfully transfected using SuperFect Reagent, as well as customer-developed transfection protocols, is available at the Transfection Tools web site www.qiagen.com/transfectiontools/.

Transfection of Neuronal PC-12 Cells Using SuperFect Reagent


Expression of green fluorescent protein (GFP) in differentiated PC-12 cells 5 days post-transfection. 104105 cells previously stimulated with 50 ng/ml NGF were plated per 60 mm dish one day prior to transfection. Transient transfections were performed in 2 ml low-serum growth medium (DMEM plus 0.05% FBS) using 3 g of a GFP-reporter plasmid and 15 l SuperFect Reagent. (Data kindly provided by K. Kelly-Spratt, University of Texas Southwestern Medical Center, Dallas, TX, USA.)

High-throughput transfection

The application of recombinant DNA technology to fields such as drug discovery and development has led to an increased need for high-throughput transfection. Transfection using SuperFect Reagent requires minimal handling, making it highly suitable for high-throughput screening. SuperFect Reagent provides high transfection efficiencies, excellent reproducibility, and low cytotoxicity in high-throughput transfection, and is available in bulk quantities.

Cited References

1. Tang, M.X., Redemann, C.T., and Szoka, Jr., F.C. (1996) In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjugate Chem. 7, 703.



'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
4. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
5. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
6. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
7. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
8. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent
9. Efficient Transfection of Neurospora Crassa
10. Eppendorf Multiporator Transfection Protocols for Eukaryotic Cells
11. Efficient Transfection of Neurospora Crassa
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... The new research portal will give ... reports on Valero Energy , offering extensive market research ... ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) The latest trend gaining ... Ethanol today, even though touted as a green alternative to ...
(Date:3/27/2017)... 27, 2017  Trovagene, Inc. (NASDAQ: TROV), a precision ... Officer, Bill Welch , will be presenting at ... 9:00 AM EDT at the Essex House in ... Chief Scientific Officer, Mark Erlander , Ph.D., will ... conference.   The presentation will be webcast live ...
(Date:3/24/2017)... MARIETTA, Ga. , March 24, 2017 ... and biopharmaceutical company utilizing human placental tissue allografts and ... therapies for multiple sectors of healthcare, announced today  that ... New York , NY.  Parker H. ... , Chief Financial Officer, Christopher M. Cashman , ...
(Date:3/24/2017)... March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or the ... China , today announced that its board of directors ... of the plan from March 27, 2017 to March 27, 2018. The ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
Breaking Biology Technology:
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
(Date:2/28/2017)... --  Acuant , a leading provider of data capture ... new and core technologies building upon the acquisition of ... desktop Acuant FRM TM facial recognition and match ... manual review of identity documents by accredited professionals. ... most accurate capture software to streamline workflows by securely ...
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
Breaking Biology News(10 mins):